

Brand and trial name	Manufacturer & launch date	Method of Delivery	Usual Dosing	Action	Antibody Specific	Vaccinations
Uplinza® (inebilizumab-cdon)	Amgen 01-2026	IV infusion	after 2 initial infusions, one dose every 6 months	Humanized monoclonal antibody targeting CD19-positive B cells	AChR and MuSK	Administer all immunizations according to guidelines at least 4 weeks prior to starting.
BKEMV™ (Interchangeable eculizumab biosimilar to Soliris®)	Amgen 03-2025	IV infusion	every 2 weeks	Monoclonal antibody that inhibits Complement C-5	Patients 6 and up AChR	serial meningococcal vaccines are required
Ephysqli® (eculizumab-aagh, a Soliris® biosimilar)	Teva 04-2025	IV infusion	900 mg weekly for first 4 weeks, 5th week 1200 mg, then 1200 mg every 2 weeks	Monoclonal antibody that inhibits Complement C-5	Patients 6 and up AChR	serial meningococcal vaccines are required
Soliris® (eculizumab)	Alexion 10-2017	IV Infusion	900 mg weekly for first 4 weeks, 5th week 1200 mg, then 1200 mg every 2 weeks	Monoclonal antibody that inhibits Complement C-5	Patients 6 and up AChR	serial meningococcal vaccines are required
Ultomiris® (ravulizumab-cwvz)	Alexion 04-2022	IV Infusion	once every 8 weeks (6-7 times a year)	Monoclonal antibody that inhibits Complement C-5	AChR	serial meningococcal vaccines are required
Zilbrysq® (zilucoplan)	UCB 01-2024	Sub-cutaneous injection and available for self-administration via pre-filled syringe	daily	Monoclonal antibody that inhibits Complement C-5	AChR	serial meningococcal vaccines are required
Imaavy® (nipocalimab-aahu)	Johnson & Johnson 04-2025	IV infusion	every 2 weeks	FcRn blocking monoclonal antibody, reducing circulating IgG	Patients 12 and up AChR, MuSK	consult physician
Rystiggo® (rozanolixizumab- noli)	UCB 07-2023	Sub-cutaneous injection to be given by healthcare professional	weekly for 6 weeks then break for 9-14 weeks, then another 6 weeks. Average 4 cycles per year	IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG	AChR, MuSK	consult physician
Vvgart® (efgartigimod alfa-fcab)	argenx 01-2022	IV Infusion	weekly for 4 weeks, individualized break before beginning another cycle but not sooner than 4 weeks from the last infusion	IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG	AChR	consult physician
Vvgart Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc)	argenx 07-2023	Sub-cutaneous injection to be given by healthcare professional and available via pre-filled syringes for self-injection	weekly for 4 weeks, individualized break before beginning another cycle but not sooner than 4 weeks from the last injection	IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG	AChR	consult physician